Feline osteoarthritis study
Study Title: Field safety and efficacy of an experimental drug compared to placebo for the treatment of pain associated with osteoarthritis in cats
Current Status: Open and enrolling
Principal Investigator: Wanda Gordon-Evans, DVM, PhD, DACVS, DACVSMR, 612-626-0646
Contact: Sara Pracht, Research Technician Specialist, 612-626-3574, email@example.com
Study purpose and design:
This study will compare a new drug to placebo for the treatment of clinical signs of osteoarthritis in cats. The new drug is a cat monoclonal nerve growth factor antibody (anti-NGF mAb). Each cat will receive a monthly subcutaneous injection for three months, followed by one final visit.
Eligible cats, briefly (contact us for full information):
- Clinical signs of osteoarthritis (OA) in two or more joints or spine
- In otherwise good health or has stable conditions
- Aged 1 year or older
- Weigh 2.0 kg (4.4 lbs) or more
- Not on certain medications or willing to withdraw from them
- Are not intended for breeding, or lactating
Study visits include screening, Day 0, 28, and 56 treatment with study drug or placebo (subcutaneous injection), and follow up visit on Day 84. Owners and the study veterinarian will complete assessments throughout the study.
Costs of the study:
The required study visits and study injections are paid for by the study. In addition, at the conclusion of the study, owners will be eligible for up to $300 as a debit card provided all study visits are completed.
To learn more, or to enroll, please contact Sara Pracht or Dr. Gordon-Evans (above).